touchIMMUNOLOGY caught up with Jonathan Bernstein (University of Cincinnati; Bernstein Allergy Group, Bernstein Clinical Research Center, Cincinnati, OH, USA) to discuss the prevalence of hereditary angioedema, lanadelumab as a treatment option, and the current challenges faced by patients.
The abstract ‘Efficacy of Lanadelumab in Hereditary Angioedema Patients With and Without Prior Use of Long-Term Prophylaxis: Final Results From the HELP Open-Label Extension Study.’ (ABSTRACT NUMBER: 462) was presented at the American Academy of Allergy, Asthma & Immunology Virtual Annual Meeting, February 26-March 1, 2021.
- Could you give us a brief overview of hereditary angioedema (HAE), its prevalence and pathogenesis? (0:20)
- Where does lanadelumab sit in the current treatment paradigm for the prevention of HAE attacks? (2:05)
- What are the challenges in individualised prescribing of lanadelumab for the prevention of HAE attacks? (3:50)
Disclosures: Jonathan Bernstein has nothing to disclose in relation to this video.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of AAAAI 2021 (Virtual).
Share this Video
Related Videos In Dermatological Conditions
Esther van Zuuren, EADV 2021: Topical Therapies in Rosacea
It was a pleasure to speak with Dr Esther van Zuuren (Leiden University Medical Centre, Leiden, the Netherlands) about current and emerging topical therapies in rosacea. Her presentation entitled ‘Update on topical drugs in rosacea‘ was received at the EADV Spring Symposium, 6-7 May 2021. Questions Could you give us an overview of the current […]
Esther van Zuuren, EADV 2021: Rosacea Classification
It was a pleasure to be able to catch up with Dr Esther van Zuuren (Leiden University Medical Centre, Leiden, the Netherlands) to discuss rosacea classification and how this can impact treatment choices. Her presentation entitled ‘Update on topical drugs in rosacea‘ was received at the EADV Spring Symposium, 6-7 May 2021. Questions Could you […]
Dedee Murrell, AAD VMX 2021: BELIEVE Phase 2 Study of Rilzabrutinib in Pemphigus
It was a pleasure to be able to speak with Prof. Dedee Murrell (St George Hospital, University of New South Wales, Sydney, Australia) about the BELIEVE Phase 2 (Part A) Study (NCT02704429) which investigated the oral BTK inhibitor, rilzabrutinib, in pemphigus. Her abstract entitled ‘Treatment With Rilzabrutinib Results in Rapid and Significant Decrease in Steroid […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!